Supraventricular TachycardiaPhase 4NCT07554170

Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in PSVT

A Phase 4 study testing Single-syringe Adenosine and Double Syringe Adenosine in people with Supraventricular Tachycardia and Supraventricular Tachycardias, run by Hormozgan University of Medical Sciences at 1 site in Iran.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable paroxysmal supraventricular tachycardia (PSVT). Read more about this study

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Supraventricular Tachycardia, Supraventricular Tachycardias, Supraventricular Arrhythmia
What is being tested?: Single-syringe Adenosine and Double Syringe Adenosine
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 134 participants
Where: 1 siteIran
Study dates: 21 May 2024to 21 Dec 2025
Phase: Phase 4
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age 18 to 80 years
Presentation to the emergency department between May 2024 and December 2025 with narrow-QRS tachyarrhythmia
Heart rate ≥150 beats/min
No visible P wave or presence of retrograde P wave on ECG
Not responsive to 2 Valsalva maneuvers lasting 15 to 30 seconds
Requiring adenosine administration

Who cannot join

Wide-QRS tachycardia or irregular R-R interval on ECG
Known allergy or contraindication to adenosine
Recent ingestion of dipyridamole, carbamazepine, or theophylline
Caffeine ingestion within the previous 2 hours
Acute asthma attack
Heart transplant
Systolic blood pressure < 90 mmHg
Previous inclusion in the trial with a second episode of re-entry tachycardia less than 4 h after the first episode.

Trial locations and contacts

1 site in 1 country.

Iran1 site

Shahid Mohammadi Hospital
Bandar Abbas

Other trials in Iran

About this study

Official title: Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in Paroxysmal Supraventricular Tachycardia: A Randomized Controlled Trial

The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable paroxysmal supraventricular tachycardia (PSVT).

Read the detailed description

The American Heart Association 2015 guidelines recommend adenosine for non-hypotensive patients with regular narrow complex PSVT. Adenosine is usually given as a rapid intravenous bolus of 6mg over 1-2 seconds, followed by a 20ml saline flush. If the first dose does not result in the termination of PSVT to normal sinus rhythm (NSR) within 1-2 minutes, a repeat dose of 12mg can be given, and the dose may be repeated one more time, if necessary, for a total of three doses.

The double-syringe technique (DST) is the standard method for administering adenosine. However, recent studies suggest that the single-syringe technique (SST) may be simpler and potentially beneficial. This technique injects adenosine and saline simultaneously at the same time instead of two separate injections. The study aims to compare the efficacy of SST and DST method for PSVT termination.

Conditions: Supraventricular Tachycardia, Supraventricular Tachycardias, Supraventricular Arrhythmia, SVT, PSVT
Being tested: Single-syringe Adenosine, Double Syringe Adenosine
Keywords: Supraventricular Tachycardia, Cardiac Arrhythmias, Cardiovascular Diseases, SVT, Single syringe, Single-syringe
Medical subject headings: Tachycardia, Supraventricular, Arrhythmias, Cardiac, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Single-syringe AdenosineDrug
Simplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 16 mL NS. A total of three doses could be provided to each patient
Double Syringe AdenosineDrug
One Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 16 mL NS. A total of three doses could be provided to each

Study groups in NCT07554170
Study group	Role	What they receive
Single-syringe technique (SST)	Experimental	Not described Receives: Drug: Single-syringe Adenosine
Double-syringe technique (DST)	Active comparator	Not described Receives: Drug: Double Syringe Adenosine

What is being measured

The primary outcome is the main question the study is designed to answer.

First-dose Successful Termination of PSVT
Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.
Measured: Within 2 minutes after administration of the first dose of adenosine.

Secondary outcomes (1)

Total Administered Dose of Adenosine.
Total cumulative dose of adenosine (mg) administered to achieve termination of PSVT.
Measured: From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

21 May 202421 Dec 2025

First posted28 Apr 2026
Study start21 May 2024
Primary completion21 Dec 2025
Study completion21 Dec 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Supraventricular TachycardiaStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 4
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 134 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07554170
Sponsor's protocol ID: PSVT management techniques
Status last verified: Aug 2026
First submitted: 6 Feb 2026
Last updated: 6 Nov 2026
Results posted: Yes, on ClinicalTrials.gov
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Arrhythmia, Bradycardia
RecruitingObservational study
AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
Tachycardia, Paroxysmal Supraventricular Tachycardia
Not yet recruiting
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
Atrial Fibrillation (AF), Atrial Flutter
Active, not recruitingPhase 1/2
Treatment of Orthostatic Intolerance
Tachycardia, Chronic Orthostatic Intolerance
Not yet recruitingObservational study
Cardiac Arrhythmias in Pediatric Emergency Department
Arrhythmias, Cardiac, Tachycardia, Supraventricular

All Supraventricular Tachycardia trials

Study at a glance

From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in Paroxysmal Supraventricular Tachycardia: A Randomized Controlled Trial
ClinicalTrials.gov ID: NCT07554170
Acronym / sponsor ID: PSVT management techniques
Conditions: Supraventricular Tachycardia, Supraventricular Tachycardias, Supraventricular Arrhythmia, SVT, PSVT
Keywords: Supraventricular Tachycardia, Cardiac Arrhythmias, Cardiovascular Diseases, SVT, Single syringe, Single-syringe
Phase: Phase 4
Study type: Interventional
Recruitment status: Completed
Enrolment: 134 participants (actual)
Lead sponsor: Hormozgan University of Medical SciencesUniversity, hospital or other
Study start: 21 May 2024 (actual)
Primary completion: 21 Dec 2025 (actual)
Study completion: 21 Dec 2025 (actual)
First posted: 28 Apr 2026 (actual)
Results: Posted 6 Nov 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable paroxysmal supraventricular tachycardia (PSVT).

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Single-syringe technique (SST)	Experimental	Drug: Single-syringe Adenosine
Double-syringe technique (DST)	Active comparator	Drug: Double Syringe Adenosine

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (6 listed)

Age 18 to 80 years
Presentation to the emergency department between May 2024 and December 2025 with narrow-QRS tachyarrhythmia
Heart rate ≥150 beats/min
No visible P wave or presence of retrograde P wave on ECG
Not responsive to 2 Valsalva maneuvers lasting 15 to 30 seconds

Key exclusion criteria (8 listed)

Wide-QRS tachycardia or irregular R-R interval on ECG
Known allergy or contraindication to adenosine
Recent ingestion of dipyridamole, carbamazepine, or theophylline
Caffeine ingestion within the previous 2 hours
Acute asthma attack

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Single-syringe AdenosineSimplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 16 mL NS. A total of three doses could be provided to each patient	Drug	Single-syringe technique (SST)
Double Syringe AdenosineOne Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 16 mL NS. A total of three doses could be provided to each	Drug	Double-syringe technique (DST)

Primary outcome

First-dose Successful Termination of PSVT
Time frame: Within 2 minutes after administration of the first dose of adenosine.
Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.

1 secondary outcome

Total Administered Dose of Adenosine.
Time frame: From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first.

Results and safety

Results posted to the registry on 6 Nov 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Single-syringe Technique (SST)	66	66
Double-syringe Technique (DST)	68	68

Primary outcome: First-dose Successful Termination of PSVT

Time frame: Within 2 minutes after administration of the first dose of adenosine.. Count of participants. Unit: Participants

Measure	Single-syringe Technique (SST) n = 66	Double-syringe Technique (DST) n = 68
Value	50	39

1 secondary outcome is reported in the full results.

Adverse events

Time frame: After adenosine administration, all patients were observed for adverse events, including hypotension, dyspnea, flushing, bradycardia, and chest pain. Monitoring was performed every 15 minutes for a duration of 30 to 60 minutes post-administration.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Single-syringe Technique (SST)	0 of 66 (0%)	4 of 66 (6.1%)	0 of 66
Double-syringe Technique (DST)	0 of 68 (0%)	25 of 68 (36.8%)	0 of 68

Limitations and caveats (from the sponsor): The study was limited by its open-label, single-center design, although the objective ECG-based assessment of PSVT termination likely reduced bias in the primary outcome. A baseline age imbalance, unavailable laboratory and clinical variables, and the lack of pharmacokinetic assessment may also have influenced the findings or limited mechanistic interpretation. Larger multicenter randomized trials are needed to confirm the results.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: No

Related trials for Supraventricular Tachycardia

RecruitingObservational study
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Arrhythmia, Bradycardia
RecruitingObservational study
AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
Tachycardia, Paroxysmal Supraventricular Tachycardia
Not yet recruiting
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
Atrial Fibrillation (AF), Atrial Flutter
Active, not recruitingPhase 1/2
Treatment of Orthostatic Intolerance
Tachycardia, Chronic Orthostatic Intolerance
Not yet recruitingObservational study
Cardiac Arrhythmias in Pediatric Emergency Department
Arrhythmias, Cardiac, Tachycardia, Supraventricular

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Nov 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First-dose Successful Termination of PSVT (time frame: Within 2 minutes after administration of the first dose of adenosine.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07554170.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.